Semax vs Dihexa: Cognitive Enhancement Peptide Comparison | Peptpedia

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a stabilized analog of ACTH(4-7) developed at the Institute of Molecular Genetics in Moscow. It stimulates the synthesis and release of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in hippocampal and cortical neurons, supporting neuronal survival, synaptic plasticity, and long-term potentiation. It also modulates the serotonin and dopamine systems through ACTH receptor interactions.

Dihexa is a modified angiotensin IV analog identified by Joseph Harding's group at Washington State University. It binds hepatocyte growth factor (HGF) and its receptor MET with extraordinarily high affinity—approximately 10 million times more potently than HGF itself. MET receptor activation in the brain promotes dendritic spine formation (synaptogenesis) and has been shown to reverse cognitive deficits in aged and cognitively impaired animals.

Semax has been a registered medicine in Russia and several CIS countries since the 1990s, approved for indications including stroke treatment and recovery, cognitive decline, and optic nerve pathology. The clinical literature — predominantly in Russian-language journals — spans multiple research institutions and clinical settings. Dolotov et al. (2006) demonstrated that Semax regulates BDNF and TrkB receptor expression in the rat hippocampus (PMID 16996037), providing a mechanistic basis for its procognitive and neuroprotective effects. Additional studies have documented its efficacy in acute ischemic stroke recovery, attention enhancement, and modulation of serotonergic and dopaminergic systems across multiple independent research groups.

Dihexa has been investigated primarily by a single research group — the Harding laboratory at Washington State University. McCoy et al. (2013) published the key pharmacological evaluation of metabolically stabilized angiotensin IV analogs, demonstrating procognitive effects in aged rats across multiple behavioral paradigms including the Morris Water Maze and passive avoidance tasks (PMID 23055539). The magnitude of cognitive reversal reported was striking: aged animals treated with Dihexa performed at levels comparable to young controls. However, no independent laboratory has replicated these findings, and no human clinical trials have been initiated.

Semax has a well-characterized safety profile derived from decades of clinical use in Russia. The intranasal administration route — nasal drops or spray — avoids systemic peptide degradation and first-pass metabolism, providing direct access to CNS tissue via the olfactory and trigeminal pathways. Published clinical data reports minimal adverse effects at therapeutic doses, with the most common being mild nasal irritation. The peptide's structural basis as an ACTH(4-7) fragment means it lacks the adrenocorticotropic activity of full-length ACTH, avoiding cortisol elevation.

Dihexa has a notable practical advantage in its oral bioavailability — unusual for a peptide compound — which simplifies administration in research settings. However, its mechanism of action raises a significant theoretical safety concern. The HGF/MET signaling pathway is a well-established driver of cancer cell migration, invasion, and metastasis. MET is classified as a proto-oncogene, and MET amplification or overactivation is documented in multiple cancer types including gastric, lung, and hepatocellular carcinoma. Chronic activation of MET by a compound with 10^7-fold potency enhancement over the natural ligand has not been evaluated in any long-term safety study, and the oncological implications remain entirely uncharacterized.

Semax has the stronger evidence base by a wide margin. As a registered medicine with clinical use spanning multiple decades, multiple research groups, and multiple therapeutic indications, it represents a well-characterized neurotrophic peptide with predictable pharmacology. Its BDNF-elevating mechanism is well understood and independently validated.

Dihexa presents a remarkable preclinical potency profile — the 10^7-fold enhancement over HGF at the MET receptor is pharmacologically extraordinary. However, it remains a single-laboratory compound with no independent replication, no human clinical data, and an unresolved oncological safety question inherent to its mechanism of action.

Important note on evidence integrity: A key paper contributing to the Dihexa mechanistic literature — Benoist et al. (2014, PMID 25187433) — has been retracted. Researchers evaluating the Dihexa evidence base should be aware of this retraction and its implications for the reliability of the published mechanistic framework. The core procognitive findings from McCoy et al. (2013) remain in the published literature but would benefit from independent replication.